GlamorousAI secures £440k grant from Innovate UK for brain tumour treatment project.
The company has received funding from Innovate UK to apply its artificial intelligence platform to glioblastoma multiforme research.
GlamorousAI is an artificial intelligence biotech company that focuses on small data drug discovery. The firm develops technologies to unlock new therapeutic opportunities in oncology and neurodegeneration.
GlamorousAI has secured £440k in grant funding from Innovate UK to support a project aimed at developing new treatments for Glioblastoma Multiforme. The company will apply its Rosalind artificial intelligence platform to discover novel therapeutic targets and biomarkers in collaboration with King's College London. The award stems from a competitive funding call that saw only 18 projects selected from over 400 applications. The initiative seeks to integrate disparate multi omics data to improve personalised therapy recommendations for patients suffering from this aggressive brain tumour.
From the founder
"The goal of GlamAI is to break new ground in applications of AI for drug discovery and accelerate the path to personalized medicine in labs around the world. We are very proud of the progress we’ve made so far to validate our approach. Through our partnership with King’s College London, GlamAI will collaborate with experts in glioblastoma multiforme and will secure access to disease cell-lines that best represent the tumor in patients. The funding received from Innovate UK is key to progress this highly innovative project and to accelerate the path to treatment for this deadly disease."
Noor Shaker
CEO at GlamorousAI
Use of funds
- 01Fund research and development
Investors
Categories
About the company
GlamorousAI
GlamorousAI develops artificial intelligence platforms for small data drug discovery.